Cheng A V, Ferrier I N, Morris C M, Jabeen S, Sahgal A, McKeith I G, Edwardson J A, Perry R H, Perry E K
MRC Neurochemical Pathology Unit, Newcastle General Hospital, Newcastle upon Tyne, U.K.
J Neurol Sci. 1991 Nov;106(1):50-5. doi: 10.1016/0022-510x(91)90193-b.
The binding of the selective 5-HT2 antagonist [3H]ketanserin has been investigated in the temporal cortex of patients with Alzheimer's disease (SDAT), Parkinson's disease (PD), senile dementia of Lewy body type (SDLT) and neuropathologically normal subjects (control). 5-HT2 binding was reduced in SDAT, PD with dementia and SDLT. SDAT showed a 5-HT2 receptor deficit across most of the cortical layers. A significant decrease in 5-HT2 binding in the deep cortical layers was found in those SDLT cases without hallucinations. SDLT cases with hallucinations only showed a deficit in one upper layer. There was a significant difference in cortical layers III and V between SDLT without hallucinations and SDLT with hallucinations. The results confirm an abnormality of serotonin binding in various forms of dementia and suggest that preservation of 5-HT2 receptor in the temporal cortex may differentiate hallucinating from non-hallucinating cases of SDLT.